| P2093 | author name string | Erik B Oleson | |
| | Joseph F Cheer | |
| P2860 | cites work | Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. | Q45099551 |
| | Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. | Q45108517 |
| | Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. | Q45988694 |
| | Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats | Q46694717 |
| | Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo | Q46755929 |
| | Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. | Q48134490 |
| | Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol | Q48141521 |
| | Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal | Q48248462 |
| | Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats | Q48419154 |
| | Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors | Q48518726 |
| | Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels | Q48518739 |
| | Marijuana: harder than thought? | Q48681171 |
| | Abstinence symptoms following smoked marijuana in humans | Q48769083 |
| | Clinical studies of cannabis tolerance and dependence | Q67501787 |
| | The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study | Q69853528 |
| | Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist | Q70911264 |
| | Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes | Q71244539 |
| | Marijuana withdrawal among adults seeking treatment for marijuana dependence | Q73312718 |
| | Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment | Q73500317 |
| | Role of endogenous cannabinoids in synaptic signaling | Q28185075 |
| | Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 |
| | Cannabinoid CB1 receptors control conditioned drug seeking | Q28259415 |
| | Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 |
| | The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission | Q28594648 |
| | Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 |
| | Determination and characterization of a cannabinoid receptor in rat brain | Q29618888 |
| | Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats | Q29619737 |
| | Cocaine receptors on dopamine transporters are related to self-administration of cocaine | Q29619876 |
| | Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum | Q30504551 |
| | The dopamine hypothesis of reward: past and current status | Q33756130 |
| | Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses | Q33940688 |
| | Cellular signal transduction by anandamide and 2-arachidonoylglycerol. | Q34098963 |
| | Endocannabinoid signaling in the brain | Q34125520 |
| | Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry | Q34176404 |
| | Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. | Q34310825 |
| | Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 |
| | Drug addiction. | Q34575484 |
| | Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 |
| | Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. | Q34605939 |
| | ??? | Q95112382 |
| | Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis | Q34631075 |
| | Brain mechanisms of drug reward and euphoria | Q34683155 |
| | Marijuana withdrawal syndrome in the animal model | Q34986723 |
| | Neural encoding of cocaine-seeking behavior is coincident with phasic dopamine release in the accumbens core and shell | Q35023233 |
| | Addictive potential of cannabinoids: the underlying neurobiology | Q35035878 |
| | Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats | Q35041427 |
| | Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure | Q35103785 |
| | The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake | Q35593066 |
| | Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. | Q36119168 |
| | Endocannabinoid signaling system and brain reward: emphasis on dopamine | Q36152336 |
| | The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? | Q36228755 |
| | The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition | Q36404693 |
| | The cannabis withdrawal syndrome | Q36448206 |
| | Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia | Q36500321 |
| | The endocannabinoid system in brain reward processes | Q36741861 |
| | Preferential enhancement of dopamine transmission within the nucleus accumbens shell by cocaine is attributable to a direct increase in phasic dopamine release events | Q36976953 |
| | Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant | Q36978979 |
| | Marijuana's interaction with brain reward systems: update 1991. | Q37028121 |
| | Neurobiological substrates for the dark side of compulsivity in addiction | Q37088658 |
| | Synaptic overflow of dopamine in the nucleus accumbens arises from neuronal activity in the ventral tegmental area | Q37171143 |
| | Dissecting motivational circuitry to understand substance abuse | Q37215613 |
| | Supply and demand for endocannabinoids | Q37867227 |
| | On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine | Q39725108 |
| | Pretreatment with δ1-tetrahydrocannabinol and psychoactive drugs: Effects on uptake of biogenic amines and on behavior | Q40285531 |
| | Cue reactivity and cue reactivity interventions in drug dependence | Q40805426 |
| | Strain-specific facilitation of dopamine efflux by Δ9-tetrahydrocannabinol in the nucleus accumbens of rat: An in vivo microdialysis study | Q41130886 |
| | THC does not affect striatal dopamine release: Microdialysis in freely moving rats | Q41141136 |
| | Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study | Q42492989 |
| | Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient | Q42502076 |
| | Influence of phasic and tonic dopamine release on receptor activation. | Q42852523 |
| | Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. | Q43562046 |
| | Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids | Q44051647 |
| | Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration | Q44051978 |
| | Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens | Q44299680 |
| | delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors | Q44345904 |
| | Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 |
| | Classically conditioned responses in opioid and cocaine dependence: a role in relapse? | Q44348701 |
| | Subsecond dopamine release promotes cocaine seeking. | Q44398175 |
| | Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 |
| | Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. | Q44723162 |
| | Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. | Q44885114 |
| | Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. | Q45080631 |
| P433 | issue | 8 | |
| P921 | main subject | dopamine | Q170304 |
| | cannabinoids | Q422936 |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | A brain on cannabinoids: the role of dopamine release in reward seeking | |
| P478 | volume | 2 | |